[CAS NO. 1032823-75-8] GSK1292263

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1032823-75-8]

Catalog

HY-12066

Brand

MCE

CAS

1032823-75-8

DESCRIPTION [1032823-75-8]

Overview

MDL	MFCD18385004
Molecular Weight	456.56
Molecular Formula	C23H28N4O4S
SMILES	CC(C1=NOC(N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(C)(=O)=O)=N1)C

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

GSK-1292263 is an orally available GPR119 agonist with pEC ₅₀ s of 6.9 and 6.7 for human and rat GPR119 , respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) ^[1] .

In Vivo

GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age) ^[2]
Dosage:	30 mg/kg
Administration:	Orally given; once a day for 2 weeks
Result:	The AUC of plasma glucose (AUC _PG ) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01128621	GlaxoSmithKline	Diabetes Mellitus, Type 2	November 23, 2009	Phase 2
NCT01218204	GlaxoSmithKline	Dyslipidaemias\|Dyslipidemias	September 14, 2010	Phase 2
NCT01119846	GlaxoSmithKline	Diabetes Mellitus, Type 2	June 5, 2009	Phase 2
NCT01101568	GlaxoSmithKline	Diabetes Mellitus, Type 2	April 14, 2010	Phase 1
NCT00783549	GlaxoSmithKline	Dyslipidaemias	September 4, 2008	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 20 mg/mL ( 43.81 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1903 mL	10.9515 mL	21.9029 mL
5 mM	0.4381 mL	2.1903 mL	4.3806 mL
10 mM	0.2190 mL	1.0951 mL	2.1903 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2 mg/mL (4.38 mM); Clear solution

* All of the co-solvents are available by MCE.